Knight Therapeutics Inc. (TSX:GUD) ("Knight"), a leading Canadian
specialty pharmaceutical company, and Ember Therapeutics, Inc.
(OTCQB:EMBT) ("Ember"), a New York-based biotech company developing
targeted therapies for osteoarthritis, kidney fibrosis, and other
regenerative medicines, today announced an expansion of their
exclusive distribution agreement signed in August 2015. Pursuant to
the amendment, Knight’s territorial rights to Ember’s Bone
Morphogenetic Protein-7 ("BMP-7") pipeline, which originally
included Canada, Israel, Russia and sub-Saharan Africa, have been
expanded to include Romania and the Caribbean. Additionally, Knight
has acquired the exclusive distribution rights for two diversified
products recently acquired by Ember: Migralex™, a
commercially-available over-the-counter medication for treating
pain, and ICX-RHY/Vavelta®, a development stage regenerative
medicine asset, in all of the above-mentioned territories.
“We are happy to have strengthened our partnership with Ember,
which has bolstered its value proposition with these recent
acquisitions,” said Jonathan Ross Goodman, President and CEO of
Knight. “Notwithstanding the currently challenging healthcare
equity markets, we are hopeful that Ember can ignite the continued
development of its BMP-7 pipeline for the treatment of
osteoarthritis and kidney fibrosis.”
“We are pleased to extend our relationship with Knight to
include not only new territories for BMP-7, but new products as
well. Over the past several months, we have significantly
strengthened our portfolio through the acquisitions of
ICX-RHY/Vavelta and Migralex, and believe that Knight is the
optimal partner to help us capture incremental value from our
commercialized product, Migralex, and maximize the impact of
ICX-RHY/Vavelta as we further advance its development,” added
Joseph Hernandez, Executive Chairman of Ember Therapeutics,
Inc.
About Migralex™
Migralex™ is a patented headache medicine containing aspirin and
magnesium that has been clinically proven to be effective in
relieving most types of pain, including arthritis pain, tension
headaches, sinus headaches, stress headaches, menstrual headaches,
and various other pains. Migralex™, which is available without a
prescription, provides fast acting relief and is gentle on the
stomach. It contains no caffeine, sodium or preservatives, and
contains magnesium as a buffering agent. Migralex™ is currently
available at CVS, local pharmacies, and online at Amazon.com and
the product website www.migralex.com.
About ICX-RHY/Vavelta®
ICX-RHY is a suspension of human dermal fibroblasts in cell
storage medium, which has demonstrated an ability in clinical and
preclinical trials to repair and rejuvenate skin. It has been
designed to improve the structure, function and appearance of skin
damaged by medical conditions such as epidermolysis bullosa,
scarring and associated scar contractures, or the aging process.
ICX-RHY is currently in early-stage clinical development.
About Ember Therapeutics Inc.
Ember Therapeutics, Inc. is a publicly traded (OTCQB:EMBT)
pharmaceutical company developing targeted therapies for pain,
osteoarthritis, kidney fibrosis and other regenerative medicines.
In particular, Ember Therapeutics, Inc. has a commercial stage pain
product and two late stage Phase 3 ready assets. For more
information, please visit www.embertx.com.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is
a specialty pharmaceutical company focused on acquiring or
in-licensing innovative pharmaceutical products for the Canadian
and select international markets. Knight Therapeutic Inc.'s shares
trade on TSX under the symbol GUD. For more information about
Knight Therapeutics Inc., please visit the company's web site at
www.gud-knight.com or www.sedar.com.
Knight Forward-Looking Statement
This document contains forward-looking statements for Knight
Therapeutics Inc. and its subsidiaries. These forward looking
statements, by their nature, necessarily involve risks and
uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Knight
Therapeutics Inc. considers the assumptions on which these
forward-looking statements are based to be reasonable at the time
they were prepared, but cautions the reader that these assumptions
regarding future events, many of which are beyond the control of
Knight Therapeutics Inc. and its subsidiaries, may ultimately prove
to be incorrect. Factors and risks, which could cause actual
results to differ materially from current expectations are
discussed in Knight Therapeutics Inc.'s Annual Report and in Knight
Therapeutics Inc.'s Annual Information Form for the year ended
December 31, 2015. Knight Therapeutics Inc. disclaims any intention
or obligation to update or revise any forward-looking statements
whether as a result of new information or future events, except as
required by law.
Ember Forward-Looking Statement
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995, regarding the research, development and commercialization of
pharmaceutical products. Such forward-looking statements are based
on current expectations and involve inherent risks and
uncertainties, including factors that could delay, divert or change
any of them, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. Forward-looking statements in the press release
should be evaluated together with the many uncertainties that
affect Ember Therapeutics’ business and Ember Therapeutics
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
For further information please contact:
Knight Therapeutics Inc. Contact:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
Tel: 514-484-GUD1 (4831)
Fax: 514-481-4116
Email: info@gud-knight.com
Website: www.gud-knight.com
Ember Therapeutics, Inc. Contact:
The Ruth Group
Lee Roth (investors)
(646) 536-7012
lroth@theruthgroup.com
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Sep 2023 to Sep 2024